TSHA Taysha Gene Therapies, Inc.

Taysha Gene Therapies is a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease. We are focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. We were founded in partnership with The University of Texas Southwestern Medical Center, or UT Southwestern, to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we are advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. By combining our management team’s proven experience in gene therapy drug development and commercialization with UT Southwestern’s world-class gene therapy research capabilities, we believe we have created a powerful engine to develop transformative therapies to dramatically improve patients’ lives.

$12.69  -0.69 (-5.16%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/24/2020
Outstanding shares:  38,473,945
Average volume:  210,893
Market cap:   $514,781,384
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    877619106
ISIN:        US8776191061
Sedol:      BNC1BX1
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.48
PS ratio:   0.00
Return on equity:   -101.47%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy